US Patent No: 7,459,544
Number of patents in Portfolio can not be more than 2000
Nucleic acids encoding B7-2 fusion proteins
Stats
-
Dec 2, 2008
Issued date -
May 2, 2003
filing date -
10/429,079
serial no -
In Force
status
Importance
Loading Importance Indicators...
Abstract
Nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation are disclosed. In one embodiment, the nucleic acid has a sequence which encodes a B lymphocyte antigen, B7-2. Preferably, the nucleic acid is a DNA molecule comprising at least a portion of a nucleotide sequence shown in FIG. 8, SEQ ID NO:1 or FIG. 14, SEQ ID NO:23. The nucleic acid sequences of the invention can be integrated into various expression vectors, which in turn direct the synthesis of the corresponding proteins or peptides in a variety of hosts, particularly eukaryotic cells, such as mammalian and insect cell culture. Also disclosed are host cells transformed to produce proteins or peptides encoded by the nucleic acid sequences of the invention and isolated proteins and peptides which comprise at least a portion of a novel B lymphocyte antigen. Proteins and peptides described herein can be administered to subjects to enhance or suppress T cell-mediated immune responses.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 5,770,197 Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules | 82 | 1993 | |
| 5,434,131 Chimeric CTLA4 receptor and methods for its use | 131 | 1993 | |
| 5,580,756 B7IG fusion protein | 70 | 1994 | |
| 6,090,914 CTLA4/CD28Ig hybrid fusion proteins and uses thereof | 42 | 1994 | |
|
|
|||
| 5,869,050 Methods of blocking T-cell activation using anti-B7 monoclonal antibodies | 13 | 1993 | |
| 5,747,034 Methods and materials for the induction of T cell anergy | 35 | 1994 | |
|
|
|||
| 6,071,716 DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells | 11 | 1993 | |
|
|
|||
| 5,116,964 Hybrid immunoglobulins | 435 | 1989 | |
|
|
|||
| 5,942,607 B7-2: a CTLA4/CD28 ligand | 34 | 1993 | |
|
|
|||
| 5,786,456 Bp 50-specific antibodies and fragments thereof | 7 | 1993 | |
|
|
|||
| 6,130,316 Fusion proteins of novel CTLA4/CD28 ligands and uses therefore | 16 | 1994 | |
|
|
|||
| 5,434,141 Medicament for the treatment of hyperlipidaemia and/or atherosclerosis | 4 | 1991 | |
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Jun 2, 2016 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jun 2, 2020 |
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge - 7.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |